Teleflex Celebrates 175,000 Patients Treated with the UroLift System

Minimally Invasive Treatment for Enlarged Prostate Provides Rapid Relief¹and Durable Results²  

WAYNE, Pa., March 11, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that 175,000 patients have now been treated globally* with its minimally invasive UroLift System—a safe and effective treatment for Benign Prostatic Hyperplasia (BPH) that provides rapid symptom relief and improved quality of life, while preserving sexual function.^**1,3

BPH, also known as enlarged prostate, is a non-cancerous enlargement of the prostate that occurs as men age. This common condition is marked by bothersome urinary symptoms, such as getting up frequently at night to urinate, that can lead to loss of productivity, depression, and decreased quality of life.⁴ BPH affects over 40 million men in the United States alone.⁵ If left untreated, the condition can worsen over time and cause permanent bladder damage.⁶

“We are gratified that physicians have entrusted the UroLift System as a treatment for 175,000 patients around the world—a testament to the demand for our proven option that may allow men to stop taking daily medication and avoid major surgery,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are pleased that growing numbers of physicians continue to adopt the UroLift System as a standard of care treatment that offers patients an effective and durable BPH solution while preserving sexual function.”^1,3

The Prostatic Urethral Lift (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. In addition to the United States and Europe, the treatment is available in Canada, Australia, New Zealand, Mexico, South Korea, Japan, Singapore, Hong Kong, and Chile.

“I have long believed that this innovative treatment would be a game-changer for the field of urology and for men suffering from enlarged prostate symptoms,” said Steven Gange, M.D., F.A.C.S.. “The robust clinical evidence supporting the UroLift System as a safe and effective treatment option provides urologists with confidence they are providing patients a procedure that offers rapid symptom relief and recovery¹. The UroLift System is the only BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction^1,3,7,8 and allows men to return to their normal routines with minimal downtime.”¹